Catalent (CTLT) Lowers FY23 Revenue Guidance

Go back to Catalent (CTLT) Lowers FY23 Revenue Guidance

Catalent (CTLT) declines again after cutting guidance

May 19, 2023 8:15 AM EDT

Shares of drug manufacturer Catalent (NYSE: CTLT) declined Friday morning after telling investors it will provide a business update today instead of a normal review of its third quarter results. This was the third time Catalent delayed the earnings release, once again citing problems with accounting adjustments.

Catalent... More

Catalent (CTLT) to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing

May 19, 2023 7:02 AM EDT

Catalent, Inc. (Catalent or the Company) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the circumstances described in the Companys Notification of Late Filing on Form 12b-25 filed on May 11, 2023 (the Form 12b-25) with the Securities and Exchange Commission (the SEC); the Companys ongoing focus on finalizing its financial statements and other disclosures in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the Form 10-Q); and completing its quarterly closing processes and procedures, it requires additional time to... More